Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

radiopharm
April 1st, 2022

Radiopharm Theranostics - Update

Another nuclear imaging and therapy company, Radiopharm Theranostics (RAD: $0.245), listed on the ASX in November last year raising $50 million at $0.60 per share.

Radiopharm has four imaging studies underway withy three therapeutic trials and an additional imaging study expected to commence by year's end. At a briefing this week, CEO Riccardo Canevari said that he expected the radiopharmaceutical market to grow very fast after the recent approval of Pluvicto, with other pharmaceutical companies waiting to enter the radiopharmaceutical sector. The three major pharmaceutical companies active in this sector are Novartis, Bayer and AstraZeneca.

1627607486842
April 1st, 2022

Chimeric Therapeutics Raises $14 Million in Rights Issue

Chimeric Therapeutics (CHM: $0.14) has raised $14.4 million through a rights issue conducted at $0.17 per share. The company finished last year with $13.4 million in cash following its IPO in January last year when the company raised $35 million at $0.20 per share.

1638225699915CEO_TEMPLATES_MAKE_DUPLICATES
February 28th, 2022

Anteris Technologies Declines Merger Proposal

Aortic heart valve development company Anteris Technologies (AVR: $18.67) has declined a proposal to merge with US cashbox company Medicus Sciences Acquisition Corp.

1635379082289CEO_TEMPLATES_MAKE_DUPLICATES_4
February 28th, 2022

Cogstate Half-Year Results

Cogstate (CGS: $1.90) reported an EBIT of US$6.1 million for the first half of this financial year. EBIT for the full year is expected to be between US$8.8 - US$11.3 million.

Pharmaxisasthmapicresized
February 14th, 2022

Pharmaxis Update

On a recent investor call, Pharmaxis (PXS: $0.097) CEO Gary Phillips said that the company's Phase I/IIa trial in patients with myelofibrosis is on target to complete recruitment by mid-year with results still due at the end of the year.

maxresdefault 1
February 14th, 2022

Chimeric Therapeutics Reports Good Data in Second Patient Cohort

Chimeric Therapeutics (CHM: $0.21) has finished dosing the second cohort of three patients in its chlorotoxin CAR-T cell therapy in patients with glioblastoma.

 

 

33251anteristechnologiespng
February 14th, 2022

Anteris Technologies Declines Merger Proposal

Aortic heart valve development company Anteris Technologies (AVR: $18.67) has declined a proposal to merge with US cashbox company Medicus Sciences Acquisition Corp.

ebr
February 14th, 2022

Why Horizon 3 Biotech Investment Committee like EBR Systems

Background
EBR Systems is a single product medical device company developing a wireless electrode designed to stimulate the left ventricle (LV) for biventricular cardiac re-synchronisation therapy (CRT). CRT is a mainstay of treatment for late-stage heart failure. The WiSE (Wireless Stimulation Endocardially) electrode represents a step change in CRT for the key reason that it is already the first ever device to achieve a CE mark for implantation to the endocardium (inside) of the left ventricle.

mqdefault
January 28th, 2022

Cogstate - US$13.7 Million of Sales Contracts Signed

Cogstate (CGS: $1.68) has delivered another good quarter of sales contracts signed, totalling US$13.7 million and $US54 million for the first half following a very strong September quarter performance.

adalta
July 27th, 2021

Adalta Moves to Inhaled Delivery for AD-214

Biologics drug development company Adalta (1AD: $0.09) has announced that its lead drug candidate, AD-214, will now be developed as an inhaled drug rather than a systemically delivered injected therapy.

The key reason for the change is that preclinical imaging studies with a radiolabelled version of AD-214 showed high accumulation levels (more than half the administered dose) in the liver. The reasons for strong binding affinity in the liver are unknown at this point, but it is not related to the i-body platform with the rapid distribution to the liver seen only with this drug candidate.

Pages